Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a higher dose of allergy medicine beat hives faster?

NCT ID NCT07236372

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares the standard dose of cetirizine (10 mg daily) to a higher dose (40 mg daily) for treating acute hives in adults. Researchers want to see if the higher dose relieves symptoms faster and reduces the need for steroid rescue medication. Participants take the assigned dose for 7 days and track their symptoms daily.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cetirizine
What this could lead to
If it works, this could offer a more effective short-term treatment for acute hives and reduce the need for steroids.
What could go wrong
This is a small, early-stage trial with only 140 participants. Higher doses may cause more side effects like drowsiness, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 60 years * Clinical diagnosis of acute urticaria made by a physician * Onset of new wheals within the past 24 hours * Able and willing to comply with study procedures, complete symptom diaries, and attend follow-up visits * Provides written informed consent prior to participation Exclusion Criteria: * Use of systemic corticosteroids within the past 5 days * Use of immunosuppressive medications within the past 5 days * Clinical signs of anaphylaxis, including respiratory distress, hypotension, abdominal pain, or acute laryngeal swelling * Presence of angioedema without wheals * Known diagnosis of chronic urticaria * Known severe renal impairment (creatinine clearance \<10 mL/min), heart failure (ejection fraction \<40%), or hepatic failure * Other skin conditions that may interfere with assessment (e.g., atopic dermatitis, eczema, bullous pemphigoid, AGEP) * Use of ACE inhibitors or ARBs within the past 5 days * Known allergy or hypersensitivity to cetirizine or components of the study medication * Pregnancy or breastfeeding * Known diabetes mellitus * History of gastrointestinal ulcer disease * Any condition that, in the investigator's judgment, would interfere with study participation or safety * Declines to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute urticaria are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Phayao Hospital

    RECRUITING

    Phayao, Mueang, 56000, Thailand